Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04026542
Other study ID # RECHMPL19_0330
Secondary ID
Status Completed
Phase
First received
Last updated
Start date September 1, 2019
Est. completion date December 31, 2020

Study information

Verified date March 2020
Source University Hospital, Montpellier
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The congenital heart disease (CHD) is the firts cause of congenital birth defects. Medical and surgical advances completely changed the epidemiology of CHD. Among these CHD, the univentricular heart, or single ventricle (SV), is a disease whose medical-surgical progress has completely changed the epidemiology. The SV at birth receives systemic and pulmonary venous returns in the single functional cavity and provides systemic and pulmonary flow. The SV undergoes a severe volumetric overload and considerably increases its work, which is not viable for the long time. In 1968, Professor Francis Fontan created the palliative surgery of the univentricular heart. It consists in establishing a derivation of the systemic venous blood from the two vena cava veins directly to the pulmonary arteries, without a sub-pulmonary ventricle. So, the VU no longer undergoes volumetric overload, and eliminates cyanosis. In this "Fontan circulation", there is no pump to push the blood in the pulmonary arteries, only the remaining systemic post-capillary energy (reflection of the central venous pressure) allows to drive the blood through the lungs with a risk of stasis upstream (right overload) and a limited pre-charge downstream, which can lead to severe consequences: limited exercise capacity, systolic and diastolic dysfunction of the SV, arrhythmia, cyanosis, cirrhosis and hepatic carcinoma, exudative enteropathy , plastic bronchitis, venous thromboses, deaths. There is a great heterogeneity within this family of SV with extremely varied evolutionary profiles. The cardiorespiratory exercise test, which has become a "gold standard", makes it possible to assess the severity of CHD. In our study on the aerobic fitness of children with CHD, the investigators found that 44% of children with SV had normal aerobic fitness (> 80% of the theoretical VO2max)1. Some good prognostic criteria are already described: left SV, good VU function, total cavopulmonary shunt in young age, etc. But the investigators know that these elements are not enough to explain why some SV, which the investigators will call the "great-SV", have a better aerobic fitness. The main objective of our study is to describe the population of "great SV" (VO2max ≥ 80%) within the general population of SV. The investigators thus wish to determine the prognostic criteria favorable to a good aerobic fitness in univenticular heart disease.


Description:

This study is cross-sectionnal, multicentric national (M3C network), descriptive, observational. Children ≥ 6 years old and adults with a single ventricle according to the international classification ACC-CHD and who had a cardiopulmonary exercise test in the year during usual follow-up will be included. Patients refuse the use of medical data will be excluded. The main objective of our study is to describe the rate of "great SV" (VO2max ≥ 80%) within the general population of SV. The secondary objectives are to compare the two groups: group "great SV" with VO2max ≥ 80% versus group SV with VO2max < 80%. The following criteria will be collected Anatomical : left SV, right SV, undetermined SV, total cavopulmoary shunt, partial cavopulmonary shunt Clinic: NYHA status, saturation, medical treatment, number of surgery procedure, number of catheterization procedure, presence of pacemaker or implantable defibrillator, presence of arrythmia. Morbidity: number oh hospitalization during the year, presence of arrhythmia, cirrhosis and hepatic carcinoma, exudative enteropathy , plastic bronchitis, venous thromboses, stroke. Echocardiography: ejection fraction of SV, 2D Strain of SV, atrioventricular valve regurgitation, aortic stenosis, aspect of the flow in the cavopulmonary shunt. Cardiac MRI: ejection fraction of SV Cardiac catheterization: mean pulmonary arterial pressure, pulmonary arterial wedge pressure, presence of fistulae. Cardiopulmonary exercise test : VO2max, anaerobic threesold, VE/VCO2 slope, oxygen uptake efficiciency slope, maximal heart rate, oxygene pulse and saturation at exercise. Pulmonary functional test : forced expiratory volume in 1 seconde (FEV1), the forced vital capacity (FVC), the FEV1/FVC ratio (FEV1/FVC%), DLCO and residual volume.


Recruitment information / eligibility

Status Completed
Enrollment 1000
Est. completion date December 31, 2020
Est. primary completion date December 1, 2020
Accepts healthy volunteers No
Gender All
Age group 6 Years and older
Eligibility Inclusion criteria: - Children = 6 years old and adults with a single ventricle according to the international classification ACC-CHD and who had a cardiopulmonary exercise test in the year during usual follow-up. Exclusion criteria: - Patients refuse the use of medical data will be excluded.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
France Uh Montpellier Montpellier

Sponsors (2)

Lead Sponsor Collaborator
University Hospital, Montpellier M3C (complex congenital heart disease) French Network

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary rate of "great SV" (VO2max = 80%) within the general population of SV measurement of the VO2max at the annual cardiopulmonary exercise test.
rate of patient who have a VO2max = 80% in this population of SV recruited.
1 day
Secondary Comparison of the 2 groups: "great SV" versus others SV. Multivariate analysis with the following data to define parameters associated with "great SV": Anatomical, Clinic, Morbidity, Echocardiography, Cardiac MRI, Cardiac catheterization, Cardiopulmonary exercise test, Pulmonary functional test 1 day
See also
  Status Clinical Trial Phase
Completed NCT05934578 - Lymphatic Function in Patients With Fontan Circulation: Effect of Physical Training N/A
Recruiting NCT05563376 - Fontan-Sprechstunde N/A
Recruiting NCT04581668 - Impact of NAVA Ventilation on Brain Oxygenation and Perfusion in Children With Congenital Heart Disease N/A
Withdrawn NCT04035317 - Aesculus Hippocastanum L. on Fontan Circulation Phase 2
Completed NCT03818373 - Respiratory Drive in Patients With Univentricular Congenital Heart Disease N/A
Recruiting NCT05620030 - Prospective Evaluation of Univentricular Hearts N/A
Recruiting NCT05744934 - Interstage Monitoring Using an Implantable Loop Recorder: A Pilot Study Early Phase 1
Withdrawn NCT03997097 - Efficacy of Phosphodiesterase-type 5 Inhibitors in Patients With Univentricular Congenital Heart Disease Phase 3
Recruiting NCT04782232 - Registry to Assess the Safety and Feasibility of the Subpulmonary Support With the Novel Venous Cannula in Patients With Failing/Absence of the Right Heart
Completed NCT04394507 - Lymphatic Function in Patients With a Fontan Circulation From Brazil
Completed NCT02283255 - Cardiovascular, Pulmonary and Skeletal Muscle Evaluation Postoperative in Fontan Patients: Effects of Exercise Training N/A
Not yet recruiting NCT05617534 - Impact of Exercise Training on Single Ventricle Function in Paediatric Fontan Patients
Completed NCT04163653 - Lymphatic Morphology of Fontan Patients
Recruiting NCT05647213 - Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease Phase 1
Recruiting NCT05454254 - Effect of Muscle Strengthening Training in Adults With Fontan Circulation N/A
Active, not recruiting NCT03379805 - Lymphatic Function in Patients With a Fontan-Kreutzer Circulation N/A